Wall Street analysts expect that Intec Pharma Ltd (NASDAQ:NTEC) will announce earnings per share of ($0.37) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Intec Pharma’s earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.38). Intec Pharma reported earnings of ($0.41) per share during the same quarter last year, which indicates a positive year over year growth rate of 9.8%. The firm is expected to issue its next quarterly earnings results on Tuesday, May 21st.

On average, analysts expect that Intec Pharma will report full year earnings of ($1.15) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.01). For the next financial year, analysts forecast that the business will report earnings of ($0.92) per share, with EPS estimates ranging from ($1.19) to ($0.68). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08).

A number of brokerages have weighed in on NTEC. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, February 12th. ValuEngine upgraded Intec Pharma from a “hold” rating to a “buy” rating in a research note on Saturday, December 1st. BidaskClub lowered Intec Pharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 6th. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the company a “buy” rating in a research note on Sunday, December 2nd. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Intec Pharma in a research note on Friday, January 4th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $12.46.

A number of large investors have recently added to or reduced their stakes in the business. PRW Wealth Management LLC bought a new position in Intec Pharma during the 4th quarter worth approximately $29,000. Reilly Financial Advisors LLC bought a new position in Intec Pharma during the 4th quarter worth approximately $38,000. BlackRock Inc. bought a new position in Intec Pharma during the 4th quarter worth approximately $67,000. PNC Financial Services Group Inc. lifted its holdings in Intec Pharma by 50.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock worth $424,000 after buying an additional 25,000 shares during the last quarter. Finally, Laurion Capital Management LP bought a new position in Intec Pharma during the 3rd quarter worth approximately $532,000. 36.43% of the stock is currently owned by institutional investors.

NASDAQ NTEC traded down $0.25 during mid-day trading on Friday, reaching $6.70. 140,687 shares of the company’s stock traded hands, compared to its average volume of 266,635. Intec Pharma has a 1-year low of $3.55 and a 1-year high of $9.25. The firm has a market cap of $228.17 million, a PE ratio of -4.79 and a beta of 0.44.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.